Understanding mTOR-associated signaling-pathway differences between EGFR TKI-sensitive and -resistant NSCLC cells is critical for targeting mTOR to overcome patient resistance after TKI treatment. This evidence concerns the gene MTOR and non-small cell lung carcinoma.